SCHEMBL618039

SCHEMBL618039

N#Cc1nc(Br)cnc1N

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.47
CSNK1A1 P48729 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
ALOX5AP P20292 3/20 0.37
FEN1 P39748 3/20 0.37
KMT2A Q03164 2/20 0.35
USP8 P40818 1/20 0.35
PIK3CD O00329 2/20 0.35
PIK3R1 P27986 1/20 0.35
ATR Q13535 1/20 0.33
ABL1 P00519 2/20 0.33
KDR P35968 1/20 0.33
MEN1 O00255 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KDM4E B2RXH2 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
GRM5 P41594 1/20 0.31
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27409647 0.82 HTT (0.36) HTTCSNK1A1CLK4USP8PIK3CD
SCHEMBL1697862 0.80 HTT (0.39) HTTCSNK1A1CLK4KDM4E
SCHEMBL31307776 0.80 HTT (0.39) HTTCSNK1A1CLK4KDM4E
SCHEMBL7781784 0.80 USP8 (0.40) HTTCSNK1A1CLK4ALOX5APFEN1
SCHEMBL1697950 0.78 CSNK1A1 (0.38) HTTCSNK1A1CLK4ALOX5APFEN1
SCHEMBL14853080 0.78 HTT (0.35) HTTKMT2AATRGRM5
SCHEMBL23508934 0.77 HTT (0.33) HTTKMT2AMEN1
SCHEMBL6375598 0.77 ALOX5AP (0.42) HTTCSNK1A1CLK4ALOX5APFEN1
SCHEMBL13346128 0.77 CSNK1A1 (0.37) HTTCSNK1A1CLK4ALOX5APFEN1
SCHEMBL845962 0.77 CSNK1A1 (0.37) HTTCSNK1A1CLK4NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521444-B Heterogeneous polymer donor material, preparation method thereof and application thereof in photovoltaic field 武汉工程大学 2024-11-12 CN claimed
CN-113106130-B Application of nitrile hydratase derived from staphylococcus aggregatus in preparation of amide pyrazine compounds 核芯生物医药科技(杭州)有限公司 2023-03-14 CN claimed
CN-113106130-A Application of nitrile hydratase derived from staphylococcus aggregatus in preparation of amide pyrazine compounds 浙江恒康药业股份有限公司 2021-07-13 CN claimed
CN-113025671-A Application of nitrile hydratase derived from sinorhizobium meliloti in preparation of amide pyrazine compounds 浙江恒康药业股份有限公司 2021-06-25 CN claimed
CN-111662938-A Application of nitrile hydratase in catalyzing hydration reaction of cyanopyrazine compound to generate amide pyrazine compound 浙江恒康药业股份有限公司 2020-09-15 CN claimed
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 EP disclosed
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2025-03-06 US disclosed
WO-2024256574-A1 PROCESS FOR PREPARING MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-12-19 WO disclosed
WO-2024256568-A1 SALT AND CRYSTAL FORMS OF A MACROCYCLIC BTK INHIBITOR CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-12-19 WO disclosed
CN-1418220-A Novel pyrazine derivative or salt thereof, pharmaceutical composition containing same, and intermediate for producing both TOYAMA CHEMICAL CO LTD (JP) 2003-05-14 CN disclosed
WO-2003031458-A1 METHODS FOR SYNTHESIS OF DIARYLMETHANES DANA-FARBER CANCER INSTITUTE (US) 2003-04-17 WO disclosed
EP-1295890-A1 Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof TOYAMA CHEMICAL CO., LTD. (JP) 2003-03-26 EP disclosed
EP-1256588-A1 NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH TOYAMA CHEMICAL CO., LTD. (JP) 2002-11-13 EP disclosed
US-5639753-A CONTROLLING INSECTS IN AGRICULTURE CROPS FMC CORPORATION (US) 1997-06-17 US disclosed
US-5532367-A LARVICIDES FMC CORPORATION (US) 1996-07-02 US disclosed
US-5521190-A USEFUL AGAINST TOBACCO BUDWORM FMC CORPORATION (US) 1996-05-28 US disclosed
WO-1994027439-A1 INSECTICIDAL PTERIDINES AND 8-DEAZAPTERIDINES FMC CORPORATION (US) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HTT 1112/4885CSNK1A1 194/4885CLK4 1215/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B HTT 2728/4885CSNK1A1 180/4885CLK4 1845/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG HTT 4371/4885CSNK1A1 301/4885CLK4 1068/4885
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS BTK, LYN, LCK HTT 3046/4885CSNK1A1 176/4885CLK4 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.